Compare OFIX & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OFIX | GOSS |
|---|---|---|
| Founded | 1987 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 534.6M | 615.7M |
| IPO Year | 1998 | 2018 |
| Metric | OFIX | GOSS |
|---|---|---|
| Price | $12.54 | $0.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $18.25 | $4.91 |
| AVG Volume (30 Days) | 279.6K | ★ 27.3M |
| Earning Date | 05-18-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.39 | ★ 78.81 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $822,312,000.00 | $114,701,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $6.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 2.85 | N/A |
| 52 Week Low | $10.25 | $0.33 |
| 52 Week High | $17.28 | $3.87 |
| Indicator | OFIX | GOSS |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 24.60 |
| Support Level | $12.33 | $0.33 |
| Resistance Level | $16.13 | $1.23 |
| Average True Range (ATR) | 0.60 | 0.10 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 19.35 | 12.16 |
Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries across the globe. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.